Summit Therapeutics (SMMT)

Common Shares
Sell: $14.70|Buy: $14.75|Change: 0.62 (-4.07%)

Company profile

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Address

136a Eastern Avenue
Milton Park
Abingdon
Oxfordshire
GBR
OX14 4SB


Telephone

+44 1235443939


Sector 

Healthcare


Previous key dates

NameKey Date
Summit Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-24T09:00:00
Summit Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-24T00:00:00
Summit Therapeutics Inc Annual Report for 20252026-02-24T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T09:45:00
Evercore Healthcare Conference2025-12-03T14:10:00
Citi’s 2025 Global Healthcare Conference2025-12-02T10:30:00
Jefferies Global Healthcare Conference2025-11-18T14:30:00
UBS Global Healthcare Conference2025-11-10T15:30:00
Summit Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-10-20T08:00:00
Summit Therapeutics ESMO Update & Q3 2025 Earnings Call2025-10-20T08:00:00
Summit Therapeutics Inc Third Quarter Earnings Result for 20252025-10-20T00:00:00
WCLC Update Call2025-09-08T08:00:00
Summit Therapeutics Inc Second Quarter Earnings Result for 20252025-08-11T00:00:00
Summit Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-11T00:00:00
Summit Therapeutics Inc Annual General Meeting for 20252025-06-12T08:30:00
46th Annual Goldman Sachs Global Healthcare Conference2025-06-09T13:20:00
Summit Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-01T16:30:00
Summit Therapeutics Inc First Quarter Earnings Results for 20252025-05-01T00:00:00
Summit Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-02-24T09:00:00
Summit Therapeutics Inc Fourth Quarter Earnings Result for 20242025-02-24T00:00:00
Summit Therapeutics Inc Annual Report for 20242025-02-24T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.